Impact of UGT2B7 (His268Tyr )polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

INTRODUCTION: Epirubicin is a common adjuvant treatment for breast cancer. It is mainly eliminated after glucuronidation through uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7). The present study aimed to describe the impact of the UGT2B7(His268Tyr )polymorphism on invasive disease-free sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Sumit, Stingl, Julia Carolin, Huber-Wechselberger, Ariana, Kainz, Alexander, Renner, Wilfried, Langsenlehner, Uwe, Krippl, Peter, Brockmöller, Jürgen, Haschke-Becher, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218946/
https://www.ncbi.nlm.nih.gov/pubmed/21658222
http://dx.doi.org/10.1186/bcr2894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218946/
https://www.ncbi.nlm.nih.gov/pubmed/21658222
http://dx.doi.org/10.1186/bcr2894

Ejemplares similares